Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 8—August 2021

Considerations for Establishing Successful Coronavirus Disease Vaccination Programs in Africa

Victor WilliamsComments to Author , Bassey Edem, Marianne Calnan, Kennedy Otwombe, and Charles Okeahalam
Author affiliations: University of the Witwatersrand School of Public Health, Johannesburg, South Africa (V. Williams, K. Otwombe); Medical Research Council Unit The Gambia at London School of Hygiene and Tropical Medicine, Fajara, The Gambia (B. Edem); University Research Co., LLC, Manila, the Philippines (M. Calnan); University of the Witwatersrand Perinatal HIV Research Unit, Johannesburg (K. Otwombe); University of the Witwatersrand Graduate School for Business Administration, Johannesburg (C. Okeahalam)

Main Article

Table 3

Guiding ethical principles when considering who should receive COVID-19 vaccine (35)*

Principle Description Practical application
Equal interest of everyone unless good reasons to justify differential prioritization
May be most appropriate to guide allocation of scarce resources among persons or populations who can be expected to derive the same benefit from the resource (e.g., high-risk populations)
Best outcomes
Allocation according to capacity to do most good or minimize most harm (e.g., saving most possible lives)
May be most appropriate to guide the allocation of scarce resources that confer substantially different benefits to different persons (e.g., groups expected to derive the most benefit)
Prioritize highest risk
Allocation to persons most at risk
May be most appropriate to guide allocation of resources intended to protect those most at risk (e.g., groups most at risk for infection and severe illness)
Prioritize those tasked with helping others Allocation to persons with certain skills that can save others or because of their participation in helping others (e.g., vaccine trial volunteers) May be most appropriate to guide allocation of resources to health care workers, first responders, vaccine trial participants, etc.

*COVID-19, coronavirus disease.

Main Article

  1. World Health Organization. WHO coronavirus disease (COVID-19) dashboard [cited 2021 May 9].
  2. Altmann  DM, Douek  DC, Boyton  RJ. What policy makers need to know about COVID-19 protective immunity. Lancet. 2020;395:15279. DOIPubMedGoogle Scholar
  3. Horton  R. Offline: COVID-19-a reckoning. Lancet. 2020;395:935. DOIPubMedGoogle Scholar
  4. Kirkcaldy  RD, King  BA, Brooks  JT. COVID-19 and postinfection immunity: limited evidence, many remaining questions. JAMA. 2020;323:22456. DOIPubMedGoogle Scholar
  5. Randolph  HE, Barreiro  LB. Herd Immunity: Understanding COVID-19. Immunity. 2020;52:73741. DOIPubMedGoogle Scholar
  6. Sewell  HF, Agius  RM, Kendrick  D, Stewart  M. Covid-19 vaccines: delivering protective immunity. BMJ. 2020;371:m4838. DOIPubMedGoogle Scholar
  7. Suthar  MS, Zimmerman  MG, Kauffman  RC, Mantus  G, Linderman  SL, Hudson  WH, et al. Rapid generation of neutralizing antibody responses in COVID-19 patients. Cell Rep Med. 2020;1:100040. DOIPubMedGoogle Scholar
  8. Phelan  AL. COVID-19 immunity passports and vaccination certificates: scientific, equitable, and legal challenges. Lancet. 2020;395:15958. DOIPubMedGoogle Scholar
  9. World Health Organization. Draft landscape and tracker of COVID-19 candidate vaccines [cited 2020 Dec 20].
  10. World Health Organization. COVID-19 vaccines [cited 2021 May 8].
  11. Centers for Disease Control and Prevention. SARS-CoV-2 variant classifications and definitions [cited 2021 May 9].
  12. World Health Organization and United Nations Children’s Fund. Progress and challenges with achieving universal immunization coverage: 2019 WHO/UNICEF estimates of national immunization coverage [cited 2020 Aug 6].
  13. Trotter  CL, Lingani  C, Fernandez  K, Cooper  LV, Bita  A, Tevi-Benissan  C, et al. Impact of MenAfriVac in nine countries of the African meningitis belt, 2010-15: an analysis of surveillance data. Lancet Infect Dis. 2017;17:86772. DOIPubMedGoogle Scholar
  14. Mahase  E. Covid-19: What do we know about the late stage vaccine candidates? BMJ. 2020;371:m4576. DOIPubMedGoogle Scholar
  15. Polack  FP, Thomas  SJ, Kitchin  N, Absalon  J, Gurtman  A, Lockhart  S, et al.; C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383:260315. DOIPubMedGoogle Scholar
  16. Ramasamy  MN, Minassian  AM, Ewer  KJ, Flaxman  AL, Folegatti  PM, Owens  DR, et al.; Oxford COVID Vaccine Trial Group. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021;396:197993. DOIPubMedGoogle Scholar
  17. World Health Organization. WHO target product profiles for COVID-19 vaccines [cited 2021 May 7].
  18. Ciabattini  A, Nardini  C, Santoro  F, Garagnani  P, Franceschi  C, Medaglini  D. Vaccination in the elderly: The challenge of immune changes with aging. Semin Immunol. 2018;40:8394. DOIPubMedGoogle Scholar
  19. van Vuuren  A, Rheeder  P, Hak  E. Effectiveness of influenza vaccination in the elderly in South Africa. Epidemiol Infect. 2009;137:9941002. DOIPubMedGoogle Scholar
  20. World Health Organization. Statement of the WHO Global Advisory Committee on Vaccine Safety (GACVS) COVID-19 subcommittee on safety signals related to the AstraZeneca COVID-19 vaccine [cited 2021 May 9].
  21. World Health Organization. Global vaccine safety. Global Advisory Committee on Vaccine Safety, 27–28 May 2020 [cited 2021 May 9].
  22. Nzolo  D, Kuemmerle  A, Lula  Y, Ntamabyaliro  N, Engo  A, Mvete  B, et al. Development of a pharmacovigilance system in a resource-limited country: the experience of the Democratic Republic of Congo. Ther Adv Drug Saf. 2019;10:2042098619864853. DOIPubMedGoogle Scholar
  23. Jusot  V, Chimimba  F, Dzabala  N, Menang  O, Cole  J, Gardiner  G, et al. Enhancing pharmacovigilance in sub-Saharan Africa through training and mentoring: a GSK pilot initiative in Malawi. [Erratum in: Drug Saf. 2021;44:723]. Drug Saf. 2020;43:58393. DOIPubMedGoogle Scholar
  24. Duclos  P. National Immunization Technical Advisory Groups (NITAGs): guidance for their establishment and strengthening. Vaccine. 2010;28(Suppl 1):A1825. DOIPubMedGoogle Scholar
  25. Sarma  H, Budden  A, Luies  SK, Lim  SS, Shamsuzzaman  M, Sultana  T, et al. Implementation of the World’s largest measles-rubella mass vaccination campaign in Bangladesh: a process evaluation. BMC Public Health. 2019;19:925. DOIPubMedGoogle Scholar
  26. Kupferschmidt  K. ‘Vaccine nationalism’ threatens global plan to distribute COVID-19 shots fairly. Science [cited 2020 Aug 6].
  27. Portnoy  A, Ozawa  S, Grewal  S, Norman  BA, Rajgopal  J, Gorham  KM, et al. Costs of vaccine programs across 94 low- and middle-income countries. Vaccine. 2015;33(Suppl 1):A99108. DOIPubMedGoogle Scholar
  28. World Health Organization. Fair allocation mechanism for COVID-19 vaccines through the COVAX facility [cited 2021 May 9].
  29. Holder  J. Tracking coronavirus vaccinations around the world. The New York Times. Updated 2021 May 8 [cited 2021 May 9].
  30. Mwai  P. British Broadcasting Corporation. Covid-19 Africa: What is happening with vaccines? Updated 2021 April 23 [cited 2021 May 9].
  31. Brew  J, Sauboin  C. A systematic review of the incremental costs of implementing a new vaccine in the expanded program of immunization in sub-Saharan Africa. MDM Policy Pract. 2019;4:2381468319894546. DOIPubMedGoogle Scholar
  32. Vaughan  K, Ozaltin  A, Mallow  M, Moi  F, Wilkason  C, Stone  J, et al. The costs of delivering vaccines in low- and middle-income countries: Findings from a systematic review. Vaccine X. 2019;2:100034. DOIPubMedGoogle Scholar
  33. Guignard  A, Praet  N, Jusot  V, Bakker  M, Baril  L. Introducing new vaccines in low- and middle-income countries: challenges and approaches. Expert Rev Vaccines. 2019;18:11931. DOIPubMedGoogle Scholar
  34. Kalantari  N, Borisch  B, Lomazzi  M. Vaccination—a step closer to universal health coverage. J Public Health. 2020:s10389–020–01322-y.
  35. World Health Organization. Global health ethics. Ethics and COVID-19: resource allocation and priority setting [cited 2021 May 8].
  36. Sallam  M. COVID-19 vaccine hesitancy worldwide: a concise systematic review of vaccine acceptance rates. Vaccines (Basel). 2021;9:160. DOIPubMedGoogle Scholar
  37. Africa Centres for Disease Control and Prevention. COVID-19 vaccine perceptions: a 15-country study [cited 2021 May 9].
  38. Benenson  S, Oster  Y, Cohen  MJ, Nir-Paz  R. BNT162b2 mRNA Covid-19 vaccine effectiveness among health care workers. N Engl J Med. 2021;384:17757. DOIPubMedGoogle Scholar
  39. Abu-Raddad  LJ, Chemaitelly  H, Butt  AA; National Study Group for COVID-19 Vaccination. Effectiveness of the BNT162b2 Covid-19 vaccine against the B.1.1.7 and B.1.351 variants. N Engl J Med. 2021;NEJMc2104974; Epub ahead of print. DOIPubMedGoogle Scholar
  40. Stranix-Chibanda  L, Brummel  S, Pilotto  J, Mutambanengwe  M, Chanaiwa  V, Mhembere  T, et al.; PROMISE study team. PROMISE study team. Slow acceptance of universal antiretroviral therapy (ART) among mothers enrolled in IMPAACT PROMISE studies across the globe. AIDS Behav. 2019;23:252231. DOIPubMedGoogle Scholar
  41. Jegede  AS. What led to the Nigerian boycott of the polio vaccination campaign? PLoS Med. 2007;4:e73. DOIPubMedGoogle Scholar
  42. Phadke  VK, Bednarczyk  RA, Salmon  DA, Omer  SB. Association between vaccine refusal and vaccine-preventable diseases in the United States: a review of measles and pertussis. JAMA. 2016;315:114958. DOIPubMedGoogle Scholar
  43. Krause  NM, Freiling  I, Beets  B, Brossard  D. Fact-checking as risk communication: the multi-layered risk of misinformation in times of COVID-19. J Risk Res. 2020;23:10529. DOIGoogle Scholar
  44. Malecki  KMC, Keating  JA, Safdar  N. Crisis communication and public perception of COVID-19 risk in the era of social media. Clin Infect Dis. 2021;72:697702. DOIPubMedGoogle Scholar
  45. World Health Organization. Risk communication and community engagement readiness and response to coronavirus disease (COVID-19): interim guidance. Updated 2020 March 19 [cited 2021 May 8].
  46. Fähnrich  C, Denecke  K, Adeoye  OO, Benzler  J, Claus  H, Kirchner  G, et al. Surveillance and Outbreak Response Management System (SORMAS) to support the control of the Ebola virus disease outbreak in West Africa. Euro Surveill. 2015;20:21071. DOIPubMedGoogle Scholar
  47. Jobanputra  K, Greig  J, Shankar  G, Perakslis  E, Kremer  R, Achar  J, et al. Electronic medical records in humanitarian emergencies - the development of an Ebola clinical information and patient management system. F1000 Res. 2016;5:1477. DOIPubMedGoogle Scholar
  48. Dong  E, Du  H, Gardner  L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020;20:5334. DOIPubMedGoogle Scholar
  49. Mpofu  M, Semo  BW, Grignon  J, Lebelonyane  R, Ludick  S, Matshediso  E, et al. Strengthening monitoring and evaluation (M&E) and building sustainable health information systems in resource limited countries: lessons learned from an M&E task-shifting initiative in Botswana. BMC Public Health. 2014;14:1032. DOIPubMedGoogle Scholar
  50. World Health Organization. Overview of VPD surveillance principles [cited 2021 May 8].

Main Article

Page created: May 27, 2021
Page updated: July 18, 2021
Page reviewed: July 18, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.